A Phase 1 interventional study of BLU-5937 IR and BLU-5937 ER in Cough and Healthy, sponsored by Bellus Health Inc. - a GSK company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-18.
Sponsored by Bellus Health Inc. - a GSK company (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing BLU-5937 in Cough — 1 open to participants now, 2 under way, 2 of them phase 3. BLU-5937 · Cough.
Among the 10 studies testing BLU-5937 in Cough, this one is the 8th largest by enrollment, is one of 3 that started in 2022, is one of 7 in phase 1, and was the 2nd registered.
428 studies on the registry are indexed under Cough; 68 are open to participants now.
Browse Cough studies →1 of the 10 studies testing BLU-5937 in Cough is open now, in 1 country. Recruiting first, the newest first:
GlaxoSmithKline · Sites in China
Ages 18–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 46 Cough studies recruiting now, 20 (43%) set no upper age limit and 14 (30%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 3 started in 2022.
This study's enrollment of 30 is below the median of 80 across 320 interventional studies indexed under Cough.
Median enrollment 44 across the 10 interventional studies. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 2 most frequent:
This study is registered under Bellus Health Inc. - a GSK company, one of the names counted as GlaxoSmithKline. Under that name alone:
Bellus Health Inc. - a GSK company is the lead sponsor of 19 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 4 (36%) have results posted.
14 studies in Cough by GlaxoSmithKline: 1 open now, 2 under way, 2 of them phase 3. Of 11 finished, 5 (45%) have results posted.
Among the 14 studies in Cough by GlaxoSmithKline, this one is the 10th largest by enrollment, is one of 3 that started in 2022, is one of 9 in phase 1, and was the 6th registered.
GlaxoSmithKline’s Cough studies by the year they started, since 2011.
1 of the studies testing BLU-5937 in Cough that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07650084Phase 3GlaxoSmithKlineA 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension | 2027-08-27 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing BLU-5937 in Cough, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 14 in Cough:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 1, Single-Centre, Open-Label, Two-Part, Sequential Cross-Over Study Designed to Assess the Pharmacokinetic Profile of BLU-5937 Following Administration of Extended Release Formulation Prototypes and an Immediate Release Reference Formulation in Healthy Male and Female Subjects
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IR Formulation
Drug: BLU-5937 IR
ER formulation
Drug: BLU-5937 ER
Each subject will receive two single and multiple administrations of Immediate Release reference formulation
Each subject will receive single and multiple oral administrations of Extended Release formulation
Measurement of the maximum observed plasma drug concentration (Cmax)
To assess the comparison between Cmax following administration of an Extended Release tablet formulation and an Immediate Release reference formulation.
Time frame: Pre dose up to 36 hours post-dose
Measurement of the minimum observed plasma drug concentration (Cmin)
To assess the comparison between Cmin following administration of an Extended Release tablet formulation and an Immediate Release reference formulation.
Time frame: Pre dose up to 36 hours post-dose
Measurement of the area under the plasma drug concentration by time curve AUC
To assess the comparison between AUC following administration of an Extended Release tablet formulation and an Immediate Release reference formulation.
Time frame: Pre dose up to 36 hours post-dose
Measurement of the observed plasma drug concentration 24 hours post-dose (C24)
To assess the comparison between C24 following administration of an Extended Release tablet formulation and an Immediate Release reference formulation.
Time frame: 24 hours post-dose
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2022 to primary completion in May 2024, 18 months.
Of 21 phase 1 interventional studies under Cough, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 18 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BLU-5937
Bellus Health Inc. - a GSK company →